List view / Grid view
24 January 2014 | By Novartis
Novartis announced it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure...
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xolair®...
12 January 2014 | By Novartis
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect...
9 December 2013 | By Novartis
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials...
6 December 2013 | By Novartis
LBH589 has potential to be the first in its class of anticancer agents available to patients with multiple myeloma...
4 December 2013 | By Novartis
"Cancer treatment has been revolutionized by targeted therapies, which have established a highly successful approach to the management of many cancers..."
29 November 2013 | By Novartis
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria...
28 November 2013 | By Novartis
Novartis scientists have discovered a new drug target for treating malaria...
14 November 2013 | By Novartis
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59® adjuvant...
11 November 2013 | By Novartis
Spain-based Grifols to acquire Novartis blood transfusion diagnostics unit for USD 1.675 billion...
22 October 2013 | By Novartis
"Novartis delivered strong sales performance in the third quarter, with all divisions contributing to growth..."
5 October 2013 | By Novartis
"The positive new data clearly show the potential of omalizumab to treat CSU, a disease where more than 50% of patients don't respond..."
4 October 2013 | By Novartis
"The data presented today are very encouraging because they are from studies that took place over four years..."
3 October 2013 | By Novartis
"Controlling relapses and preventing disability are key treatment goals for patients with MS..."
1 October 2013 | By Novartis
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed...
